Transarterial chemoembolization versus resection for the intermediate stage hepatocellular carcinoma
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background/Aims: Several studies have suggested that surgical resection (SR) can provide a survival benefit over transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) at the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) staging system. However, the criteria for SR remain to be determined. This study compared the long-term outcome of intermediate-stage HCC patients treated by either TACE or SR as a primary treatment modality, with the aim of identifying the patient subgroup that gained a survival benefit by either modality. Methods: In total, 277 BCLC intermediate-stage HCC patients treated by either TACE (N=225) or SR (N=52) were analyzed. Results: The overall median survival time was significantly better for SR than TACE (61 vs. 30 months, P=0.002). Decision-tree analysis divided patients into seven nodes based on tumor size and number, serum alpha-fetoprotein (AFP) level, and Child-Pugh score, and these were then simplified into four subgroups (B1–B4) based on similarities in the overall hazard rate. SR provided a significant survival benefit in subgroup B2, characterized by ‘oligo’ (2–4) nodules of intermediate size (5–10 cm) when the AFP levels was <400 ng/ml, or ‘oligo’ (2–4) nodules of small to intermediate size (<10 cm) plus a Child-Pugh score of 5 when the AFP level was ≥400 ng/mL (median survival 73 vs. 28 months for SR vs. TACE respectively; P=0.014). The survival rate did not differ significantly between SR and TACE in the other subgroups (B1 and B3). Conclusions: SR provided a survival benefit over TACE in intermediate-stage HCC, especially for patients meeting certain criteria. Re-establishing the criteria for optimal treatment modalities in this stage of HCC is needed to improve survival rates.
Abstract
Background/Aims: Several studies have suggested that surgical resection (SR) can provide a survival benefit over transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) at the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) staging system. However, the criteria for SR remain to be determined. This study compared the long-term outcome of intermediate-stage HCC patients treated by either TACE or SR as a primary treatment modality, with the aim of identifying the patient subgroup that gained a survival benefit by either modality. Methods: In total, 277 BCLC intermediate-stage HCC patients treated by either TACE (N=225) or SR (N=52) were analyzed. Results: The overall median survival time was significantly better for SR than TACE (61 vs. 30 months, P=0.002). Decision-tree analysis divided patients into seven nodes based on tumor size and number, serum alpha-fetoprotein (AFP) level, and Child-Pugh score, and these were then simplified into four subgroups (B1–B4) based on similarities in the overall hazard rate. SR provided a significant survival benefit in subgroup B2, characterized by ‘oligo’ (2–4) nodules of intermediate size (5–10 cm) when the AFP levels was <400 ng/ml, or ‘oligo’ (2–4) nodules of small to intermediate size (<10 cm) plus a Child-Pugh score of 5 when the AFP level was ≥400 ng/mL (median survival 73 vs. 28 months for SR vs. TACE respectively; P=0.014). The survival rate did not differ significantly between SR and TACE in the other subgroups (B1 and B3). Conclusions: SR provided a survival benefit over TACE in intermediate-stage HCC, especially for patients meeting certain criteria. Re-establishing the criteria for optimal treatment modalities in this stage of HCC is needed to improve survival rates.
참고문헌 (22)
- Llovet JM, "Hepatocellular carcinoma", Lancet, 362, pp.1907~1917 (2003)
- European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival", Hepatology, 37, pp.429~442 (2003)
- Bolondi L, "Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions", Semin Liver Dis, 32, pp.348~359 (2012)
- Ho MC, "Liver resection improves the survival of patients with multiple hepatocellular carcinomas", Ann Surg Oncol, 16, pp.848~855 (2009)
- Hsu CY, "Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis", Ann Surg Oncol, 19, pp.842~849 (2012)
- Zhong JH, "Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma", Tumour Biol, 35, pp.8355~8358 (2014)
- Lee HS, "Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study", J Clin Oncol, 20, pp.4459~4465 (2002)
- Korean Liver Cancer Study Group, National Cancer Center, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- Roayaie S, "The role of hepatic resection in the treatment of hepatocellular cance", Hepatology, 62, pp.440~451 (2015)
- Yau T, "Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma", Gastroenterology, 146, pp.1691~1700.e3 (2014)
- Yin L, "Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT", J Hepatol, 61, pp.82~88 (2014)
- Romagnoli R, "Surgical resection for hepatocellular carcinoma: Moving from what can be done to what is worth doing", Hepatology, 62, pp.340~342 (2015)
- Zhong JH, "Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma", Ann Surg, 260, pp.329~340 (2014)
- Weichselbaum RR, "Oligometastases revisited", Nat Rev Clin Oncol, 8, pp.378~382 (2011)
- Yamakado K, "Treatment strategies of intermediate-stage hepatocellular carcinomas in Japan (Barcelona Clinic Liver Cancer stage B)", Oncology, 87(Suppl 1), pp.78~81 (2014)
- Jianyong L, "Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?", Medicine (Baltimore), 93, pp.e180~ (2014)
- Kang SH, "Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels", Eur J Gastroenterol Hepatol, 24, pp.849~856 (2012)
- Heng-jun G, "Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma", Liver Int, 34, pp.612~620 (2014)
- Korean Association for the Study of the Liver, "KASL Clinical practice guidelines: Management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
- 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 발행위원회